Cure My Disease

Don't miss your cure!

 Log in / Sign up

NIH launches study to uncover clues in mood disorder treatments

NCT ID NCT06462196

Knowledge-focused Sponsor: National Institute of Mental Health (NIMH) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 6 times

Summary

This study follows 500 adults already receiving care for depression, bipolar disorder, or suicide risk at the NIH. Researchers will conduct weekly interviews and optional tests like blood draws and brain scans to track symptoms and treatment responses. The goal is to better understand how these disorders affect the body and find ways to predict which medications work best, especially for suicidal thoughts.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors predict which medications might reduce suicidal thoughts, improving personalized treatment for mood disorders.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to immediate changes in care, and results depend on participant cooperation and existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with depression, bipolar disorder, and individuals at elevated suicide risk.

Ages

18 to 120 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Signed consent for Protocol 01-M-0254: The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Volunteers * Age 18 years or older * Able to provide informed consent * Able to read and write English EXCLUSION CRITERIA: * Unstable medical conditions in the opinion of the investigator that would preclude participation in outpatient or inpatient treatment. * Pregnancy * Participation in the Protocol 01-M-0254: The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Volunteers, as a healthy volunteer. * Participants with a history of DSM-IV substance or alcohol abuse or dependence, or DSM-5 substance use disorder (except for caffeine, nicotine, or cannabis), or moderate to severe alcohol use disorder, within the preceding three months. In addition, participants who are currently using drugs (except for caffeine, nicotine, or cannabis) must not have used illicit substances or known drugs of abuse in the two weeks prior to consent and must have a negative drug urine test (except for prescribed benzodiazepines or stimulants) prior to enrolling in the study. Cannabis use is exclusionary if the use is daily, or if participants are unable to abstain during the study, or if function of daily life is impaired by use as determined by a clinician.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Analgesics are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Behavioral Symptoms bipolar depression bipolar disorder Depression depressive disorder Depressive Disorder, Treatment-Resistant major depressive disorder Self-Injurious Behavior Suicide

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Analgesics Anesthetics Anesthetics, dissociative Anesthetics, general Behavioral symptoms Central nervous system depressants Depression, bipolar Depression, unipolar Depressive symptoms Excitatory amino acid agents Excitatory amino acid antagonists Ketamine Major depressive disorder Molecular mechanisms of pharmacological action Neurotransmitter agents Peripheral nervous system agents Physiological effects of drugs Self-injurious behavior Sensory system agents Suicide Treatment resistant depression

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.